Headlands Research Acquires Eastern Massachusetts–Based Research Site
Headlands Research has announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease for over 25 years.
Headlands Research Eastern Massachusetts is led by founder and Principal Investigator (PI) Donald Marks, MD, a board-certified neurologist specializing in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and related disorders who also currently serves on the staff of the Division of Neurology at Beth Israel Deaconess Hospital—Plymouth. Marks conducted his first clinical trial in 1993, evaluating tacrine, the first drug approved for the treatment of Alzheimer’s disease, and in 2008, Marks and his team began research on disease-modifying drugs (DMDs) for Alzheimer’s disease. To date, Marks and his team have conducted 41 clinical trials, with 36 focusing on Alzheimer’s disease. The team has been in an accelerated growth phase—13 of the 36 Alzheimer’s disease trials have been started since 2020.
Reference
Headlands Research Acquires Established Eastern Massachusetts–Based Research Site Specializing in Neurodegenerative Diseases. (2023, April 18). Business Wire.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
